Previous close | 30.77 |
Open | 30.85 |
Bid | 30.31 x 100 |
Ask | 30.48 x 100 |
Day's range | 29.48 - 31.25 |
52-week range | 25.60 - 77.60 |
Volume | |
Avg. volume | 493,583 |
Market cap | 750.551M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Aligns Closely With Analyst Projections Amidst Strategic Clinical Advancements
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.